The latest news on Eltrombopag/Eltrombopag being included in medical insurance

As of late May 2024, the original drug Eltrombopag/Eltrombopag has been marketed and sold in China under the nameEltrombopag ethanolamine tablets, and has successfully entered the national medical insurance directory. This means that eligible patients can enjoy relevant reimbursement and compensation from the medical insurance policy. After entering the medical insurance directory, patients can purchase Eltrombopag ethanolamine tablets through a doctor's prescription and pay part of the cost through medical insurance, reducing the patient's financial burden.

Eltrombopag is an orally bioavailable small molecule drug mainly used to treat chronic immune, idiopathic, and chronic hepatitis C thrombocytopenia (ITP). In recent years, Eltrombopag has made significant breakthroughs in the treatment of thrombocytopenia. Due to its outstanding efficacy and wide application in clinical practice, Eltrombopag can stimulate the bone marrow to produce more platelets, helping patients with thrombocytopenia to increase platelet levels and reduce the risk of bleeding.

Eltrombopag ethanolamine tablets are included in the scope of Class B medical insurance, and there are certain restrictions on reimbursement. Currently, medical insurance reimbursement is mainly limited to adults and children aged 6 and above with chronic immune (idiopathic) thrombocytopenia who have had poor response to glucocorticoids, immune globulin and other treatments in the past; or patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive treatment in the past. This means that only patients who meet these conditions can enjoy reimbursement from medical insurance.

In general, the inclusion of eltrombopag in medical insurance is good news. It not only provides financial support to patients, but also further promotes the treatment of thrombocytopenia. The current price of original drugs sold in China can reach up to more than 4,000 yuan. After reimbursement, patients can better afford the price of the drug.